Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RxSight, Inc.RXST · Entity 1226 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RxSight, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,076 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 78,076 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 12,149 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 5,190 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Includes 5,190 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:10 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 37,037 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-275856 · ownership.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,076 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:37 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 10,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081960 · ownership.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,039 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 3, 2025. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 01:26 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 12,149 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-005764 · form4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2 · shares: Includes 5,190 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:25 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 2,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-071326 · ownership.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,287 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 6, 2024. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 21:03 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-013480 · form4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,149 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| April 24, 2024 Filed May 31, 2024 21:01 UTC Amendment | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 4,126 | $42.41 | $174,983.66 |
DisclosureSEC source: 0001127602-24-017136 · form4a.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,149 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:10 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 7,220 | $43.42 | $313,504.67 |
DisclosureSEC source: 0000950170-24-003339 · ownership.xml · nonDerivative · entry 2 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on August 24, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 7,220 shares sold in the price range of $43.085 to $43.98 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Cabo Living Trust, for which the Reporting Person serves as trustee. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:10 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 16,530 | $42.37 | $700,389.32 |
DisclosureSEC source: 0000950170-24-003339 · ownership.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 7,220 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on August 24, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 16,530 shares sold in the price range of $42.00 to $42.995 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Cabo Living Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 23:49 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 5,498 | $35.08 | $192,845.10 |
DisclosureSEC source: 0001209191-23-058376 · doc4.xml · nonDerivative · entry 2 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 23,750 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on August 24, 2023 by the Reporting Person. F4 · price: Represents the weighted average share price of an aggregate total of 5,498 shares sold in the price range of $35.00 to $35.20 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Cabo Living Trust, for which the Reporting Person serves as trustee. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 23:49 UTC | RxSight, Inc. RXST · Entity 1226 | SaleCommon Stock | 14,502 | $35.01 | $507,706.32 |
DisclosureSEC source: 0001209191-23-058376 · doc4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 29,248 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted on August 24, 2023 by the Reporting Person. F2 · price: Represents the weighted average share price of an aggregate total of 14,502 shares sold in the price range of $35.00 to $35.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares held by the Cabo Living Trust, for which the Reporting Person serves as trustee. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:37 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 5,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034345 · doc4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,733 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 1, 2023. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 22:09 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 2,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016356 · form4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,023 F1 · shares: Represents RSUs granted on May 18, 2023, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2024 annual meeting. Read SEC document |
| June 02, 2022 Filed Jun 4, 2022 00:25 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 8,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034397 · doc4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,002 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the date immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 2, 2022. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:31 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 2,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015866 · form4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,611 F1 · shares: Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:27 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantCommon Stock | 3,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-002325 · primarydocument.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,191 F1 · shares: Represents Restricted Stock Units that vest 1/3 on each of the first, second and third anniversary of the grant date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:14 UTC | RxSight, Inc. RXST · Entity 1226 | PurchaseCommon Stock | 43,750 | $16.00 | $700,000.00 |
DisclosureSEC source: 0000899243-21-031808 · doc4.xml · nonDerivative · entry 3 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 57,128 F4 · ownership.nature: Shares held by the Cabo Living Trust, for which the Reporting Person serves as trustee. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:14 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 7,645 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031808 · doc4.xml · nonDerivative · entry 2 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,378 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F3 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one third of the RSUs subject to the award shall vest on each annual anniversary of August 3, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 23:14 UTC | RxSight, Inc. RXST · Entity 1226 | GrantCommon Stock | 5,733 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031808 · doc4.xml · nonDerivative · entry 1 Warner Robert Keith · CIK 0001874373 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,733 F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following August 3, 2021. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.